ATE297916T1 - Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel - Google Patents

Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel

Info

Publication number
ATE297916T1
ATE297916T1 AT00901292T AT00901292T ATE297916T1 AT E297916 T1 ATE297916 T1 AT E297916T1 AT 00901292 T AT00901292 T AT 00901292T AT 00901292 T AT00901292 T AT 00901292T AT E297916 T1 ATE297916 T1 AT E297916T1
Authority
AT
Austria
Prior art keywords
heteroaryl
anticancer agent
substituted quinolin
derivatives usable
usable
Prior art date
Application number
AT00901292T
Other languages
German (de)
English (en)
Inventor
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE297916T1 publication Critical patent/ATE297916T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00901292T 1999-02-11 2000-02-04 Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel ATE297916T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11970299P 1999-02-11 1999-02-11
PCT/IB2000/000121 WO2000047574A1 (en) 1999-02-11 2000-02-04 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
ATE297916T1 true ATE297916T1 (de) 2005-07-15

Family

ID=22385869

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00901292T ATE297916T1 (de) 1999-02-11 2000-02-04 Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel

Country Status (39)

Country Link
US (3) US6258824B1 (enExample)
EP (1) EP1150973B1 (enExample)
JP (3) JP4090200B2 (enExample)
KR (1) KR20010102073A (enExample)
CN (1) CN1340051A (enExample)
AP (1) AP2001002241A0 (enExample)
AR (1) AR028985A1 (enExample)
AT (1) ATE297916T1 (enExample)
AU (1) AU2124800A (enExample)
BG (1) BG105860A (enExample)
BR (1) BR0008202A (enExample)
CA (1) CA2362394C (enExample)
CO (1) CO5140097A1 (enExample)
CZ (1) CZ20012910A3 (enExample)
DE (1) DE60020812T2 (enExample)
DZ (1) DZ3009A1 (enExample)
EA (1) EA200100766A1 (enExample)
EE (1) EE200100425A (enExample)
ES (1) ES2243228T3 (enExample)
GT (1) GT200000014A (enExample)
HK (1) HK1042096A1 (enExample)
HN (1) HN2000000019A (enExample)
HR (1) HRP20010574A2 (enExample)
HU (1) HUP0105231A3 (enExample)
ID (1) ID29584A (enExample)
IL (1) IL144307A0 (enExample)
IS (1) IS5997A (enExample)
MA (1) MA26718A1 (enExample)
NO (1) NO20013909L (enExample)
OA (1) OA11833A (enExample)
PA (1) PA8490601A1 (enExample)
PE (1) PE20001464A1 (enExample)
PL (1) PL349839A1 (enExample)
SK (1) SK11002001A3 (enExample)
SV (1) SV2001000020A (enExample)
TN (1) TNSN00028A1 (enExample)
TR (2) TR200201297T2 (enExample)
WO (1) WO2000047574A1 (enExample)
ZA (1) ZA200106520B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545020B1 (en) * 1998-07-06 2003-04-08 Janssen Pharmaceutica, N.V. Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties
KR20010102073A (ko) * 1999-02-11 2001-11-15 실버스타인 아써 에이. 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체
PT1230232E (pt) * 1999-11-05 2004-07-30 Cytovia Inc 4h-cromeno substituido e seus analogos como activadores de caspases e indutores de apoptose e sua utilizacao
DE60008206T2 (de) * 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1253921A4 (en) * 2000-01-28 2004-10-13 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
ATE321038T1 (de) 2000-09-25 2006-04-15 Janssen Pharmaceutica Nv Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
WO2002024686A2 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7173040B2 (en) 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
JP4974439B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
IL155163A0 (en) * 2000-10-02 2003-10-31 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
DE60139080D1 (de) 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
US20040067968A1 (en) * 2000-12-27 2004-04-08 Angibaud Patrick Rene Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline
WO2002051835A1 (en) 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
ES2337558T3 (es) * 2001-05-16 2010-04-27 Cytovia, Inc. 4-h-cromenos sustituidos y analagos como activadores de caspasas e inductores de apoptosis y uso como agentes anticancerigenos.
WO2002092076A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
EP1458720B1 (en) 2001-12-19 2009-03-18 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ATE364384T1 (de) 2002-03-22 2007-07-15 Janssen Pharmaceutica Nv Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
UA78548C2 (en) * 2002-03-29 2007-04-10 Janssen Pharmaceutica Nv Radiolabelled quinoline and quinolinone derivatives and use thereof as metabotropic ligands of glutamate receptor
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
WO2003096982A2 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003097806A2 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
JP3814285B2 (ja) * 2002-12-19 2006-08-23 ファイザー・インク 眼疾患の治療に有用なプロテインキナーゼ阻害剤としての２−（１ｈ−インダゾール−６−イルアミノ）−ベンズアミド化合物
RS53118B (sr) 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
TW200504057A (en) * 2003-02-27 2005-02-01 Chugai Pharmaceutical Co Ltd Benzothiophene derivative
JP2006528193A (ja) * 2003-07-22 2006-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼの阻害剤としてのキノリノン誘導体
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
WO2006021886A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
AU2005294430A1 (en) * 2004-10-07 2006-04-20 Cytovia, Inc. Substituted N-aryl-1H-pyrazolo[3,4-b]quinolin-4-amines and analogs as activators of caspases and inducers of apoptosis
AU2006275528B2 (en) 2005-07-29 2012-03-08 Children's Hospital Medical Center GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
KR101536506B1 (ko) * 2005-09-07 2015-07-14 암젠 프레몬트 인코포레이티드 액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP1968591A4 (en) * 2005-12-23 2010-02-17 Link Medicine Corp TREATMENT OF SYNUCLEINOPATHIES
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
ES2392630T3 (es) 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF
DK2155733T3 (da) * 2007-05-23 2012-10-29 Allergan Inc Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
AU2008256926B2 (en) * 2007-05-23 2013-09-19 Allergan, Inc. ((Bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists
US8129356B2 (en) * 2007-10-01 2012-03-06 Vanderbilt University Bmx mediated signal transduction in irradiated vascular endothelium
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
MX2011005096A (es) * 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012517426A (ja) 2009-02-09 2012-08-02 アステックス ファーマシューティカルズ インコーポレイテッド ピロロピリミジニルａｘｌキナーゼ阻害剤
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
JP6466335B2 (ja) 2012-10-16 2019-02-06 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲ−γ−Ｔのメチレン連結キノリニルモジュレーター
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
CN105873439A (zh) 2013-10-15 2016-08-17 詹森药业有限公司 RORγt的烷基连接的喹啉基调节剂
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
MX2018006781A (es) 2015-12-03 2018-11-09 Agios Pharmaceuticals Inc Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
CN108003150A (zh) * 2016-10-31 2018-05-08 河南工业大学 4-杂芳基喹啉酮衍生物的制备方法及其应用
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
EP4013402B1 (en) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732531A1 (de) * 1977-07-19 1979-02-01 Hoechst Ag Imidazolcarbonsaeuren und deren derivate
US4835154A (en) * 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US5136085A (en) * 1990-11-28 1992-08-04 Glaxo Inc. Synthesis of 2-aminobenzophenones
US5053543A (en) * 1990-11-28 1991-10-01 Glaxo Inc. Synthesis of 2-aminobenzophenones
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EE03484B1 (et) * 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
ATE222104T1 (de) * 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
TR200101343T2 (tr) 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
KR20010102073A (ko) * 1999-02-11 2001-11-15 실버스타인 아써 에이. 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체

Also Published As

Publication number Publication date
NO20013909L (no) 2001-10-08
EE200100425A (et) 2002-12-16
TR200201297T2 (tr) 2002-06-21
HUP0105231A2 (hu) 2002-04-29
CO5140097A1 (es) 2002-03-22
US6388092B2 (en) 2002-05-14
HRP20010574A2 (en) 2002-12-31
JP2005002124A (ja) 2005-01-06
EA200100766A1 (ru) 2002-02-28
TNSN00028A1 (fr) 2005-11-10
OA11833A (en) 2005-08-23
CA2362394A1 (en) 2000-08-17
CA2362394C (en) 2006-01-17
HK1042096A1 (zh) 2002-08-02
IL144307A0 (en) 2002-05-23
AR028985A1 (es) 2003-06-04
DE60020812D1 (de) 2005-07-21
SK11002001A3 (sk) 2002-05-09
HUP0105231A3 (en) 2003-01-28
IS5997A (is) 2001-07-10
PE20001464A1 (es) 2000-12-20
AP2001002241A0 (en) 2001-09-30
US6710209B2 (en) 2004-03-23
EP1150973A1 (en) 2001-11-07
EP1150973B1 (en) 2005-06-15
MA26718A1 (fr) 2004-12-20
NO20013909D0 (no) 2001-08-10
JP4216740B2 (ja) 2009-01-28
DZ3009A1 (fr) 2004-03-27
SV2001000020A (es) 2001-11-08
BR0008202A (pt) 2002-02-19
US20020120145A1 (en) 2002-08-29
ID29584A (id) 2001-09-06
ES2243228T3 (es) 2005-12-01
PA8490601A1 (es) 2002-07-30
WO2000047574A1 (en) 2000-08-17
HN2000000019A (es) 2001-07-30
DE60020812T2 (de) 2006-05-04
BG105860A (en) 2002-03-29
TR200201296T2 (tr) 2002-07-22
AU2124800A (en) 2000-08-29
JP2004182741A (ja) 2004-07-02
US6258824B1 (en) 2001-07-10
US20020019530A1 (en) 2002-02-14
GT200000014A (es) 2001-08-03
ZA200106520B (en) 2002-08-26
JP4090200B2 (ja) 2008-05-28
JP2002536444A (ja) 2002-10-29
KR20010102073A (ko) 2001-11-15
CN1340051A (zh) 2002-03-13
CZ20012910A3 (cs) 2002-02-13
PL349839A1 (en) 2002-09-23

Similar Documents

Publication Publication Date Title
ATE349440T1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
ATE359275T1 (de) Substituierte bizyclische derivate verwendbar als antitumor mittel
EE200100425A (et) Heteroarüül-asendatud kinoliin-2-ooni derivaadid kui vähivastased vahendid
ATE275553T1 (de) Isothiazole derivate verwendbar als antikrebsmittel
ATE321037T1 (de) Als antikrebsmittel verwendbare alkinyl- substituierte chinolin-2-on-derivate
DE60009147D1 (de) Admantan derivate
DE60207815D1 (de) 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden
DE60036053D1 (de) Erythropoietin Derivate
ATE253067T1 (de) Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
ATE316528T1 (de) Neue benzimidazol derivate verwendbar als antiproliferative mittel
DE60013127D1 (de) 5-phenyl-pyrimidine derivate
DE122007000076I1 (de) Pleuromutlin derivate als antimikrobielles Wirkungsmittel
ATE293618T1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
EE200200064A (et) Arüülmetüülkarbonüülaminotiasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena
PT1198453E (pt) Derivados de n-(indolcarbonil)-piperazina como ligandos do receptor 5-ht2a
ATE273980T1 (de) 6-phenylpyrrolopyrimidindion derivate
ATE240943T1 (de) Isochinolin derivate als urokinase inhibitoren
EE200200204A (et) Asendatud bensimidasooli preparaat
ATE254621T1 (de) Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten
ATE317389T1 (de) 4-phenyl-pyrimidine derivate
ATE325123T1 (de) Imidazoquinoline derivate als adenosine a3 rezeptor liganden
ATE230405T1 (de) 2-phenylpyran-4-one derivate
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
DE60143905D1 (de) Phtalazinon derivate
DE69838303D1 (de) Hydroxyprolin derivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties